BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37633414)

  • 21. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
    Klyuchnikov E; Holler E; Bornhäuser M; Kobbe G; Nagler A; Shimoni A; Könecke C; Wolschke C; Bacher U; Zander AR; Kröger N
    Br J Haematol; 2012 Oct; 159(2):172-81. PubMed ID: 22909192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
    Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
    Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
    Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study.
    Zhang R; Wang L; Chen P; Gao X; Wang S; Li F; Dou L; Gao C; Li Y; Liu D
    Cancer Med; 2021 May; 10(10):3165-3176. PubMed ID: 33932107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.
    Hernández-Boluda JC; Pereira A; Kröger N; Beelen D; Robin M; Bornhäuser M; Angelucci E; Vitek A; Blau IW; Niittyvuopio R; Finke J; Cornelissen JJ; Passweg J; Dreger P; Petersen E; Kanz L; Sanz J; Zuckerman T; Zinger N; Iacobelli S; Hayden P; Czerw T; McLornan D; Yakoub-Agha I
    Leukemia; 2021 Jan; 35(1):215-224. PubMed ID: 32286544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Donor Lymphocyte Infusion From Two Types of Donors on Mixed Chimerism With Secondary Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation.
    Ren RR; Ma LM; Xie YX; Tian WW; Wang T
    Transplant Cell Ther; 2022 Mar; 28(3):152.e1-152.e7. PubMed ID: 34973501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
    Patriarca F; Sperotto A; Lorentino F; Oldani E; Mammoliti S; Isola M; Picardi A; Arcese W; Saporiti G; Sorasio R; Mordini N; Cavattoni I; Musso M; Borghero C; Micò C; Fanin R; Bruno B; Ciceri F; Bonifazi F
    Front Oncol; 2020; 10():572918. PubMed ID: 33178602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Guisnel C; Schirmer L; Morisset S; Robin M; Labussière-Wallet H; Dulery R; Ceballos P; Forcade E; Nguyen-Quoc S; Poire X; Maertens J; Chantepie S; Chevallier P; Daguindau E; Villate A; Charbonnier A; Castilla-Llorente C; Contentin N; Huynh A; Yakoub-Agha I; Bulabois CE; Rubio MT; D'Aveni M
    Acta Haematol; 2023; 146(3):230-239. PubMed ID: 36603565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
    Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
    Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
    Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
    Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.
    Schneidawind C; Jahnke S; Schober-Melms I; Schumm M; Handgretinger R; Faul C; Kanz L; Bethge W; Schneidawind D
    Br J Haematol; 2019 Jul; 186(1):60-71. PubMed ID: 30916396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Calmels B; Oudin C; Lemarie C; Granata A; Devillier R; Vey N; Bouabdallah R; Chabannon C; Blaise D
    Exp Hematol; 2013 Jan; 41(1):17-27. PubMed ID: 23022128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
    Hua J; Zhang J; Zhang X; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu C; Chen S; Tang X; Wu D; Qiu H
    Bone Marrow Transplant; 2021 May; 56(5):1056-1064. PubMed ID: 33235353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
    Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV
    Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.